In our latest HealthDay Now interview, Mabel Jong heard from experts with inside knowledge on the FDA's controversial approval of aducanumab.

First up is Dr. G. Caleb Alexander, a professor at Johns Hopkins who served on the FDA advisory committee that nearly unanimously advised against approving Biogen's controversial new Alzheimer's drug. Then, a conversation between Dr. Anton Porsteinsson, a principal investigator for the drug trial, and Dr. Ken Lin, a primary care physician who, like most clinicians surveyed in a new poll, has his concerns and has said he will not prescribe the new drug.

Watch the in-depth discussion above, and see our past HealthDay Nows and other videos on our YouTube channel.